Barclays analyst Luke Sergott maintains $10x Genomics (TXG.US)$ with a buy rating, and adjusts the target price from $21 to $19.
According to TipRanks data, the analyst has a success rate of 39.8% and a total average return of -4.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $10x Genomics (TXG.US)$'s main analysts recently are as follows:
10x Genomics endured a challenging quarter influenced by a commercial reorganization and a subdued genomics capital expenditure environment. It is anticipated that this period represents the low point of the demand environment, and the restructuring is expected to begin yielding modest improvements as genomics capital expenditure demand starts to recover.
Following the Q3 report, 10x Genomics has seen an adjustment in the fiscal 2024 guidance, reduced by $50M at the midpoint, indicating a forecast for flat sequential revenue in Q4, which falls short of the general consensus. The recent weakness is primarily ascribed to disruptions caused by commercial and organizational transitions, compounded by tough macroeconomic conditions.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克莱银行分析师Luke Sergott维持$10x Genomics (TXG.US)$买入评级，并将目标价从21美元下调至19美元。
根据TipRanks数据显示，该分析师近一年总胜率为39.8%，总平均回报率为-4.8%。
此外，综合报道，$10x Genomics (TXG.US)$近期主要分析师观点如下：
受商业重组和低迷的基因组资本支出环境的影响，10x Genomics经历了一个充满挑战的季度。预计这一时期是需求环境的低点，随着基因组学资本支出需求开始恢复，预计重组将开始产生适度的改善。
继第三季度报告发布后，10x Genomics调整了2024财年的指导方针，在中点减少了5000万美元，这表明预计第四季度连续收入将持平，未达到普遍共识。最近的疲软主要归因于商业和组织转型造成的混乱，再加上艰难的宏观经济状况。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
